📰 Checkmate 816 News
Checkmate 816 News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Checkmate 816. Real-time updates on events, politics, business and more.
November 10, 2023
An expert comparison of recent data on neoadjuvant and perioperative immunotherapy in resectable early-stage NSCLC, including CheckMate 77T, CheckMate-816, and KEYNOTE-671.
October 12, 2023
Specialists engage in a conversation regarding the treatment duration and the effectiveness of the current two-year approach.
July 14, 2023
Jarushka Naidoo, MBBCh, discussed the clinical significance of datasets from several phase 3 trials presented at the 2023 ASCO Annual Meeting, including ADAURA, KEYNOTE-617, CheckMate 816, and CheckMate 9LA trials.
May 5, 2023
Shared insight from key opinion leaders on the value of molecular testing in patients with resectable non–small cell lung cancer and how it can be applied.
April 28, 2023
Focused discussion on the selection of neoadjuvant therapy in patients with resectable NSCLC in light of recent clinical trials.